ArticleBritish journal of clinical pharmacology2026
Pharmacogenetic CYP2B6 variants affect steroid hormone metabolism in human breast cancer cells.
Article in British journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pharmacogenetic CYP2B6 variants affect steroid hormone metabolism in human breast cancer cells.British journal of clinical pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
aimsCYP2B6 is a key enzyme involved in the metabolism of steroid hormones such as testosterone and estradiol. Common genetic CYP2B6 variants (*4, *5, *6, *9) are associated with reduced enzymatic activity and have been linked to increased breast cancer risk and poor prognosis. However, the impact of these genetic variants on testosterone and estradiol metabolism in humans is not understood. Therefore, this study aimed to investigate how these pharmacogenetic CYP2B6 variants affect metabolism of these steroid hormones in a human breast cancer model and how this may contribute to altered steroid hormone profiles in breast cancer.
methodsT47D breast cancer cells were engineered to stably overexpress CYP2B6 wild type and the variants *4, *5, *6 and *9 using a retroviral pMOWS vector system. The metabolites 16α-/16β-hydroxytestosterone and 2-/4-hydroxyestradiol were analysed using HPLC-MS/MS after incubation of testosterone or estradiol with CYP2B6 and CYP1B1 supersomes and the modified T47D cells. Conversion of testosterone metabolites to oestrogens by aromatase was also tested.
resultsCYP2B6 supersomes predominantly formed 16β-hydroxytestosterone and 2-hydroxyestradiol, while CYP1B1 predominantly produced 16α-hydroxytestosterone and 4-hydroxyestradiol. CYP2B6*6 overexpression in T47D increased 16α-hydroxytestosterone formation, while *4 and 9 showed decreased metabolism compared to wild type. CYP2B6*5 produced reduced 16β-hydroxytestosterone levels. Aromatase converts 16α-metabolite to estriol and 16β-hydroxytestosterone to 16-epiestriol.
conclusionsThis study demonstrates that common CYP2B6 variants alter testosterone metabolism in a human breast cancer model, potentially disrupting steroid hormone balance and contributing to a tumour-promoting environment. These findings highlight the potential relevance of pharmacogenetic profiling in breast cancer risk assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.